Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016
Go back to Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.75 -0.1 (3.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.85 | 52 Week High | $8.30 | |||
| Open | $2.84 | 52 Week Low | $2.43 | |||
| Day High | $2.90 | P/E | N/A | |||
| Day Low | $2.74 | EPS | $-0.22 | |||
| Volume | 438,582 | |||||
